Triton Systems is a Global Business Venture company that successfully launches innovative products and solutions in emerging markets worldwide. We invest in new technologies through in-house incubation and external partnerships – creating thriving businesses from novel ideas.

Business Ventures

Triton commercializes innovative technologies and transforms them into successful businesses. From cancer treatment to flame retardant plastic to waste water management, we impact global markets creating $3.8 Billion in shareholder value.

Ventures Include:

Aduro Biotech

Aduro Biotech (Aduro), a Triton launched company formed in 2010, stays at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination; that make transformative advances in the treatment of challenging diseases.

FRX Polymers, Inc.

FRX Polymers, Inc., a (formed by Triton in 2007) manufactures Nofia® polyphosphonates - fire resistant plastics. Nofia products are fully transparent, high flowing and, due to their high phosphorus content, are inherently flame retardant. 

Emefcy

Emefcy specializes in developing energy-efficient wastewater treatment solutions. The company’s innovative Membrane Aerated Biofilm Reactor (MABR) technology is installed at sites around the world.

Sensera

Sensera is an integrated, fast turnaround client-specific designer and manufacturer of specialized high performance microsensors and micro-fabricated components for the Healthcare, Industrial, Defense and Aerospace markets.

Emerging Technologies

Key to our process is to research, identify and incubate emerging technologies that are in line with our strategic market focus. Through our in-house incubation operations or through outside partnerships and adopted technologies, we provide market driven solutions that effect the world around us. Emerging technologies include:

Featured Incubated Products

Traceptor™ Preconcentrator

A Plug and Play ‘Sensitivity Amplifier’ that enables chemical sensors for threat and contraband detection.

MEMS Sensors & Manufacturing

Triton designs, engineers and manufactures MEMS-based sensors and other devices for industrial, medical and defense applications.

FRA Composites
(Fiber Reinforced Aluminum)

Triton FRA Composites is a fiber reinforced aluminum composite that offers light weight and high strength alternatives to heavy steel for bearing applications.

Latest News

Triton Receives Tibbetts Award at White House Ceremony

January 10, 2017, Chelmsford, MA:Triton Systems, Inc. (Triton) announced today that it has received a Tibbetts Award from the US Small Business Administration during a White House ceremony in Washington D.C. This prestigious national award award is given to companies who have successfully leveraged Small Business Innovation Research (SBIR) grants and have generated great value to the firm and to the nation.

Read More

Triton Announces Launch of Sensera Inc to Focus on Rapidly Growing Microsensors and Microcomponents Business

Transaction positions the company in the Rapidly Growing IoT Sensors Revolution

October 25, 2016, Chelmsford, MA: Triton Systems Inc. (Triton), a technology and business venturing company, today announced the acquisition of its microsensor and microcomponent business, Sensera Inc (Sensera) by Sensera Pty Ltd, headquartered in Melbourne, Australia.  Sensera will continue to operate in Chelsmford, Massachuetts and will focus on the design and manufacturing of specialized high performance microsensors and micro-fabricated components for the healthcare, industrial, security and aerospace and defense markets.

Read More

 

 

Aduro Biotech Announces Clinical Collaboration with Merck to Evaluate the Combination of Aduro’s CRS-207 with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Gastric Cancer

BERKELEY, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today a clinical collaboration with Merck (known as MSD outside the United States and Canada). The companies will investigate the combination of CRS-207, Aduro’s LADD (live, attenuated double-deleted) based immunotherapy, with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of gastric cancer.

Read More

 

Emefcy Group Limited Announces First China Demonstration Plant In Operation And Commissioned Ahead of Schedule

December 14, 2016 Melbourne, Australia and Caesarea, Israel: Emefcy Group Limited (ASX: EMC) (“Emefcy”) is pleased to announce that less than two weeks since arriving on site, its first demonstration packaged plant is in operation and has been commissioned ahead of schedule at, one of the top institutes in China and an ideal, state-of-the-art location for Chinese customers to visit. Wuxi Municipal Design Institute is a subsidiary of the Wuxi Guolian Environmental & Energy Group Co. Ltd. (“Wuxi Guolian”), a leading state-owned enterprise and provider of environmental protection services throughout Jiangsu, mainland China, and international markets. Wuxi was the first of several Chinese sales distribution partnerships announced by Emefcy Group.

Read More